Tools   Select Another Resource Report Type

http://www.ttuhsc.edu/centers/aging/giabrainbank.aspx

The Brain Bank was developed with two service-minded objectives: provide a free brain autopsy to confirm clinical diagnosis of dementia, and collect, bank and provide brain tissue to qualified scientific researchers studying diseases related to dementia. By working together, patients and researchers can help us understand the origins of neurodegenerative disease and eventually improve the treatment and care of dementia. The clinical diagnosis of Alzheimer's disease can only be confirmed by brain autopsy, or the examination of brain tissue after death. This examination will determine a patients's precise type of dementia. To confirm the diagnosis of Alzheimer's, for example, the brain tissue is examined for amyloid plaques and neurofibrillary tangles by a neuropathologist. The presence of these plaques and tangles will verify the clinical diagnosis of Alzheimer's disease. While it is important to us to enroll patients with dementia, it is equally important to enroll people with no dementia. These subjects are termed as controls and the brain tissue from controls will enable researchers to make comparisons to brain tissue from dementia patients. We are seeking donations from individuals who have had an age-related neurodegenerative disease like Alzheimer's, Parkinson's, Lewy Body or other related dementia.

Proper citation: GIA Brain Bank Program (RRID:SCR_008877) Copy   

•   Source: SciCrunch Registry

http://adc.med.nyu.edu/

The NYU Alzheimer's Disease Center is part of the Department of Psychiatry at New York University School of Medicine. The center's goals are to advance current knowledge and understanding of brain aging and Alzheimer's disease, to expand the numbers of scientists working in the field of aging and Alzheimer's research, to work toward better treatment options and care for patients, and to apply and share its findings with healthcare providers, researchers, and the general public. The ADC's programs and services extend to other research facilities and to healthcare professionals through the use of its core facilities. The NYU ADC is made up of seven core facilities: Administrative Core, Clinical Core, Neuropathology Core, Education Core, Data Management and Biostatistics Core, Neuroimaging Core, and Psychosocial Core.

Proper citation: NYU Alzheimer's Disease Center (RRID:SCR_008754) Copy   

•   Source: SciCrunch Registry

http://www.ohsu.edu/xd/research/centers-institutes/neurology/alzheimers/research/data-tissue/neuro-imaging.cfm

NeuroImaging laboratory focused on detecting early brain changes associated with cognitive decline and dementia that manages the neuroimaging component of all studies at the Layton Aging and Alzheimer's Center including acquisition and archival services, as well as volumetric analysis of anonymized MRI scans. Assistance with resulting data is also available, including statistical analysis, and preparation of materials for presentation and publication. The Layton Center also manages a library of thousands of digitized MRI scans, including what is believed to be the largest collection of longitudinal MRI scans of cognitively intact elderly subjects. The OADC Neuroimaging Lab conducts MRI studies on both 3 and 7T MRI systems using advanced sequences, employing a multimodal approach to brain imaging research.

Proper citation: Layton Center NeuroImaging Laboratory (RRID:SCR_008823) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/cndr/biosamples-brainbank.html

A brain and tissue bank that contains human brain samples from patients with Alzheimer's disease (AD), Parkinson's disease (PD) and other related neurodegenerative dementias and movement disorders. This brain bank serves as a resource for scientists and researchers, providing access to tissue samples for further research. While priority is given to University of Pennsylvania researchers, this bank will provide requests to researchers not associated with the University of Pennsylvania. This tissue bank accepts donations from those seeing a University of Pennsylvania physician or collaborator.

Proper citation: University of Pennslyvania Brain Bank (RRID:SCR_008820) Copy   

•   Source: SciCrunch Registry

http://www.nimh.nih.gov/educational-resources/brains-inner-workings/the-brains-inner-workings-activities-for-grades-9-through-12.shtml

This comprehensive free collection of multimedia resources and inquiry-based activities tied to the National Science Education Standards help teachers and students learn about the structure, function and cognitive aspects of the human brain. The packet includes a teacher's manual, student manual, DVD of videos, and a CDROM of accompanying materials.

Proper citation: Brain's Inner Workings: Activities for Grades 9 through 12 (RRID:SCR_008842) Copy   

•   Source: SciCrunch Registry

http://psychiatry.stanford.edu/alzheimer/

Portal for gerontology research with a variety of clinical, research and educational programs, with the aim of improving the lives of those affected by Alzheimer's Disease and memory losses associated with normal aging. The Center investigates the nature of Alzheimer's Disease, its progression over time, its response to treatments, and problems patients and caregivers experience in dealing with the changes that occur. It also conducts studies that look at changes that occur over the course of normal aging and have a Normal Aging Brain Donor Program. The Aging Clinical Research Center puts out a newsletter that showcases various projects and includes informative articles on dementia.

Proper citation: Stanford/VA Aging Clinical Research Center (RRID:SCR_008678) Copy   

•   Source: SciCrunch Registry

http://www.muschealth.com/multimedia/Podcasts/index.aspx?type=main

The MUSChealth.com Podcast Library, featuring podcasts on a variety of topics related to your health and our services here at MUSC. These medical podcasts are hosted by MUSC faculty, physicians and special guests and are produced and directed by Linda Austin, M.D. Current topics include: * Academics and Education * Aging, Geriatrics and Caregiving * Alcohol and Drug Dependency * Allergies and Asthma * Ashley River Tower * Bones, Joints, Muscles and Spine * Cancer * Children''s Health * Cosmetic Surgery * Dental * Dermatology/Skin Problems * Diabetes, Endocrinology and Metabolism * Digestive Health * ENT: Ear, Nose and Throat * Executive Health * Eye Health * General Health and Wellness * Heart and Vascular Health * Hospice * Kohl''s Take a Minute for Kids * Lungs and Breathing * Men''s Health * Mental Health * MUSC News and Events * Neurological Health * Organ Transplant * Osteoporosis * Pregnancy - Week by Week * Pregnancy and Childbirth * Radiology * Research and Clinical Trials * SC Health, Leadership and Policy * Sports Medicine * Stroke * Urology * Weight Loss Surgery Follow-up * Weight Management * Women''s Health

Proper citation: MUSC Health Podcast Library (RRID:SCR_008827) Copy   

•   Source: SciCrunch Registry

http://www.ucl.ac.uk/tapb/

We aim to facilitate the pathway for access, storage, use and transfer of human organs, cells and tissue between clinical centers within UCL Partners, academic groups in UCL, other universities, hospitals, medical researcher and biotechnology companies, to enhance the ability for researchers to access the materials they need. Alongside this, researchers will be able to exchange information and access guides on regulatory, ethics and practical issues concerning access, transfer and use of this type of material. These guides will be video and documents format, based on talks at organized events given by experts in the relevant fields. All of this information will be accessible on a website that seeks to link groups within UCL and attract attention from the wider world through social media and expansion of existing contacts. Our vision is to develop a centralized human tissue provision and utilization service for academic and commercial researchers UCL has the highest concentration of biomedical researchers in Europe. As part of this, UCL has numerous licensed biobanks and is associated with many research intensive hospitals in North London. The role of a biobank is to prepare and hold human tissue samples in for use by medical researchers to help delivery new treatments. Hospitals can also provide human tissue for research by utilizing waste human tissue taken as part of surgery or diagnostic procedures, but is normally incinerated. The researchers using the human tissue could be working within academic laboratories in UK universities and institutions or as part of commercial companies. Researchers currently cannot easily access human tissue to meet the demands of their research, often due to the long ethical, regulatory and contractual processes. However, with the enormous UCL biobanking and research Hospital resources, UCL could be a leading academic institution in providing human tissue for medical research within the UK and internationally. Our vision is to develop a centralized human tissue provision and utilization service for academic and commercial researchers. This relies on creating an overarching infrastructure, to consolidate information on disparate human tissue resources around UCL, and (where possible) gain centralized ethical and regulatory and contractual approval for use of the tissue. Funding the infrastructure will rely on a cost recovery model for a per sample basis. As a result the time needed to obtain tissue for research will be dramatically reduced, whilst providing a simple costing model for obtaining human tissue. This will make human tissue procurement much more efficient for end users.

Proper citation: Tissue Access for Patient Benefit (RRID:SCR_008853) Copy   

•   Source: SciCrunch Registry

http://commonfund.nih.gov/Proteincapture/

Program that is developing new resources and tools to understand the critical role the multitude of cellular proteins play in normal development and health as well as in disease. These resources will support a wide-range of research and clinical applications that will enable the isolation and tracking of proteins of interest and permit their use as diagnostic biomarkers of disease onset and progression. The program is being implemented in phases, with three Funding Opportunity Announcements (FOAs): * FOA 1: Antigen Production (RFA-RM-10-007) To produce human transcription factor antigens for making monoclonal antibodies or other affinity capture reagents; this effort is already underway. * FOA 2: Anti-Transcription Factor Antibodies Production (RFA-RM-10-017) To optimize and scale anti-transcription factor capture reagent production to develop a community antibody resource. * FOA 3: New Reagent Technology Development and Piloting (RFA-RM-10-018) To develop improvements in the reagent production pipeline with regard to quality, utility, cost, and production scalability. To understand what makes a cell function normally and what may go awry in disease, we need better tools and resources, such as renewable protein capture reagents and probes, to study how proteins work in isolation and how they interact with other proteins, carbohydrates, or DNA regions within a cell. Ideally, this resource would allow us to identify and isolate all proteins within cells, in their various forms the so called proteome to ensure broad application in research and clinical studies aimed at understanding, preventing, detecting and treating disease. Existing protein capture reagents, such monoclonal antibodies, have been developed for a number of protein targets, although these represent only a subset of all proteins comprising the human proteome. In addition, many monoclonal antibodies lack the desired level of specificity and do not reliably target only the protein of interest. This is particularly problematic given the multiple forms of any one protein and the broad range of protein types in the body. The Protein Capture Reagents Program is organized as a pilot program using transcription factors as a test case to examine the feasibility and value of generating a community resource of low cost, renewable affinity reagents for all human proteins. The reagents must be specifically designed for high quality and broad experimental utility in order to meet the growing demands of biomedical researchers. Based on what is learned from these funding initiatives, the program may expand to a larger production effort to provide a broad community resource of human protein capture reagents.

Proper citation: Common Fund Protein Capture Reagents (RRID:SCR_006570) Copy   

•   Source: SciCrunch Registry

http://www.niaid.nih.gov/topics/alps/Pages/default.aspx

A disease-related portal about Autoimmune Lymphoproliferative Syndrome (ALPS) including research in the following categories: Medical and Genetic Description, Database of Mutations, Database of ALPS-FAS Mutations, and Molecular Pathways. Autoimmune Lymphoproliferative Syndrome (ALPS) is a recently recognized disease in which a genetic defect in programmed cell death, or apoptosis, leads to breakdown of lymphocyte homeostasis and normal immunologic tolerance. It is an inherited disorder of the immune system that affects both children and adults. In ALPS, unusually high numbers of white blood cells called lymphocytes accumulate in the lymph nodes, liver, and spleen, which can lead to enlargement of these organs. Database of Mutations * All existing ALPS-FAS mutations (NIH Web site) * ALPS-FAS * ALPS Type Ia (most common type) ** Reported FAS (TNFRSF6) mutations causing ALPS ** Distribution of FAS (TNFRSF6) mutations ** FAS (TNFRSF6) polymorphisms * ALPS Type II

Proper citation: Autoimmune Lymphoproliferative Syndrome Information (RRID:SCR_006451) Copy   

•   Source: SciCrunch Registry

http://www.casacolumbia.org

A science-based organization focused on developing effective solutions to address the disease of addiction and reduce the risks associated with substance use. CASAColumbia works to: * Close the gap between what is known about addiction and what is actually done to prevent and treat it * Incorporate addiction prevention and treatment into routine health care and medical practice * Explore the possibility of finding a cure Founded by Former U.S. Secretary of Health, Education, and Welfare Joseph A. Califano, Jr., CASA remains the only national organization that assembles under one roof all of the professional skills needed to research and develop proven, effective ways to prevent and treat substance abuse and addiction to all substances - alcohol, nicotine as well as illegal, prescription and performance enhancing drugs - in all sectors of society. CASAColumbia is committed to understanding the science of addiction and its implications for health care, public policy and public education.

Proper citation: CASA (RRID:SCR_006607) Copy   

•   Source: SciCrunch Registry

http://www.autoimmunitycenters.org/

Nine centers that conduct clinical trials and basic research on new immune-based therapies for autoimmune diseases. This program enhances interactions between scientists and clinicians in order to accelerate the translation of research findings into medical applications. By promoting better coordination and communication, and enabling limited resources to be pooled, ACEs is one of NIAID''''s primary vehicles for both expanding our knowledge and improving our ability to effectively prevent and treat autoimmune diseases. This coordinated approach incorporates key recommendations of the NIH Autoimmune Diseases Research Plan and will ensure progress in identifying new and highly effective therapies for autoimmune diseases. ACEs is advancing the search for effective treatments through: * Diverse Autoimmunity Expertise Medical researchers at ACEs include rheumatologists, neurologists, gastroenterologists, and endocrinologists who are among the elite in their respective fields. * Strong Mechanistic Foundation ACEs augment each clinical trial with extensive basic studies designed to enhance understanding of the mechanisms responsible for tolerance initiation, maintenance, or loss, including the role of cytokines, regulatory T cells, and accessory cells, to name a few. * Streamlined Patient Recruitment The cooperative nature of ACEs helps scientists recruit patients from distinct geographical areas. The rigorous clinical and basic science approach of ACEs helps maintain a high level of treatment and analysis, enabling informative comparisons between patient groups.

Proper citation: Autoimmunity Centers of Excellence (RRID:SCR_006510) Copy   

•   Source: SciCrunch Registry

http://projectreporter.nih.gov/project_info_description.cfm?aid=8661937&icde=19363283&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC

Initiative to assemble a multicenter team of expert neuroscientists to evaluate the late effects of Traumatic brain injury (TBI), including single and repetitive TBI of varying severity, and Chronic Traumatic Encephalopathy (CTE), using histological examination of postmortem bio specimens and neuroimaging tools as a foundation to develop in vivo diagnostics. As a first aim, this proposal will bring together a team of 5 accomplished neuropathologists in neurodegenerative disease to establish consensus criteria for the post-mortem diagnosis of CTE. This team will also define the stages of CTE pathology, the features that differentiate CTE from other neurodegenerations and the effects of substance abuse, and the characteristics of posttraumatic neurodegeneration after single TBI. As a second aim, this proposal will establish a national bio specimen and data bank for TBI (Understanding Neurological Injury and Traumatic Encephalopathy (UNITE) bio bank) by developing a nationwide brain donor registry and hotline to acquire high quality bio specimens and data. The UNITE bank will use strictly standardized protocols and a web-based interface to ensure that tissue and data are readily available to qualified investigators. Comprehensive retrospective clinical data including clinical symptoms, brain trauma and substance abuse history, and medical records (including common data elements) will be entered into a secure database. Behavioral/ mood dysfunction, cognitive changes, substance abuse and traumatic exposure will be correlated with quantitative assessment of the multifocal tauopathy, Ass deposition and axonal injury. As a third aim, neuroimaging signatures of the neuropathology will be determined in post-mortem tissue using high spatial resolution diffusion tensor imaging (DTI) and autoradiography using a highly selective PET ligand for tau. Quantitative assessment of axonal injury, tau, and Ass will be correlated with ex vivo DTI abnormalities and tau ligand autoradiography. Pilot neuroimaging studies of individuals at high risk for the development of CTE will also be conducted in the final 2 years of the proposal. This proposal will determine the clinical and neuroimaging correlates of CTE and posttraumatic neurodegeneration and create the groundwork for establishing their incidence and prevalence. This study will have a tremendous impact on public health of millions of Americans and greatly increase our understanding of the latent effects of brain trauma.

Proper citation: CTE and Post-traumatic Neurodegeneration: Neuropathology and Ex Vivo Imaging (RRID:SCR_006543) Copy   

•   Source: SciCrunch Registry

http://www.alzforum.org/

A community building portal dedicated to understanding Alzheimer's disease and related disorders, it reports on the latest scientific findings from basic research to clinical trials, creates and maintains public databases of essential research data and reagents, and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across disciplines.

Proper citation: Alzheimer's Research Forum (RRID:SCR_006416) Copy   

•   Source: SciCrunch Registry

http://www.rarechromo.org/html/home.asp

Unique is a source of information and support to families and individuals affected by any rare chromosome disorder and to the professionals who work with them. Unique is a UK-based charity but welcomes members worldwide. Unique''''s Karyotype Database allows users to search the Registered Chromosome Disorders by chromosome, arm and disorder. You may have been given a diagnosis or indication of a chromosome disorder by a geneticist or other medical professional and they may have used a medical term which is unfamiliar to you. So to help you decide if Unique is the appropriate organization for you, we thought it would be useful to describe the different categories of rare chromosome disorder. Rare chromosome disorders can be grouped as structural disorders, numerical disorders and other miscellaneous disorders. Unique: * acts as an international family support group * produces a newsletter three times each year * works to promote awareness of rare chromosome disorders * arranges for families to assist in research into rare chromosome disorders * links families whose children have similar clinical and/or practical problems * works to ensure that the public at large are aware of rare chromosome disorders * works to raise funds to support the group activities and produce literature to make others more aware of our children''''s conditions * assists relevant research projects and the centralisation of information, at all times observing the need for total confidentiality * sets up local groups throughout the UK for families affected by any rare chromosome disorders and to give support and encouragement to each other * develops and maintains a comprehensive computerised database detailing the life-time effects of specific chromosome disorders on affected members * aims to hold an annual conference where families and relevant specialists can meet and be informed of the latest medical, technical and practical developments * liaises and works in co-operation, with other similar support groups and professionals world-wide for the benefit of families and individuals affected by rare chromosome disorders * ensures that hospitals, doctors, health authorities, genetic clinics and other professionals are aware of the group so that we may have early contact with families where required Membership of Unique is free but the group receives no government funding and is heavily reliant on donations and fundraising to continue its work. Please help us in whatever way you can.

Proper citation: Unique (RRID:SCR_006492) Copy   

•   Source: SciCrunch Registry

http://www.nkdep.nih.gov/lab-evaluation/gfr-calculators.shtml

Glomerular Filtration Rate (GFR) calculators to estimate kidney function for adults (MDRD GFR Calculator) and children (Schwartz GFR Calculator). In adults, the recommended equation for estimating glomerular filtration rate (GFR) from serum creatinine is the Modification of Diet in Renal Disease (MDRD) Study equation. The IDMS-traceable version of the MDRD Study equation is used. Currently the best equation for estimating glomerular filtration rate (GFR) from serum creatinine in children is the Bedside Schwartz equation for use with creatinine methods with calibration traceable to IDMS. Using the original Schwartz equation with a creatinine value from a method with calibration traceable to IDMS will overestimate GFR.

Proper citation: Glomerular Filtration Rate Calculators (RRID:SCR_006443) Copy   

•   Source: SciCrunch Registry

http://www.LOVD.nl/

Freely available tool for Gene-centered collection and display of DNA variations. It also provides patient-centered data storage and storage of Next Generation Sequencing (NGS) data, even of variants outside of genes. Please note that LOVD provides a system for storage of information on genes and allelic variants. To obtain information about any genes or variants, do not download the LOVD package. This information should be obtained from the respective databases, http://www.lovd.nl/2.0/index_list.php In total: 2,507,027 variants (2,208,937 unique) in 170,935 individuals in 62619 genes in 88 LOVD installations. (Aug. 2013) LOVD 3.0 shared installation, http://databases.lovd.nl/shared/genes To maintain a high quality of the data stored, LOVD connects with various resources, like HGNC, NCBI, EBI and Mutalyzer. You can download LOVD in ZIP and GZIPped TARball formats.

Proper citation: Leiden Open Variation Database (RRID:SCR_006566) Copy   

•   Source: SciCrunch Registry

http://www.nkdep.nih.gov/lab-evaluation/gfr/creatinine-standardization.shtml

Standard specification to reduce inter-laboratory variation in creatinine assay calibration and therefore enable more accurate estimates of glomerular filtration rate (eGFR). Created by NKDEP''''s Laboratory Working Group in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the European Communities Confederation of Clinical Chemistry (now called the European Federation of Clinical Chemistry and Laboratory Medicine), the effort is part of a larger NKDEP initiative to help health care providers better identify and treat chronic kidney disease in order to prevent or delay kidney failure and improve patient outcomes. Recommendations are intended for the USA and other countries or regions that have largely completed standardization of creatinine calibration to be traceable to an isotope dilution mass spectrometry (IDMS) reference measurement procedure. The program''''s focus is to facilitate the sharing of information to assist in vitro diagnostic manufacturers, clinical laboratories, and others in the laboratory community with calibrating their serum creatinine measurement procedures to be traceable to isotope dilution mass spectrometry (IDMS). The program also supports manufacturers'''' efforts to encourage their customers in the laboratory to coordinate use of standardized creatinine methods with implementation of a revised GFR estimating equation appropriate for use with standardized creatinine methods. Communication resources and other information for various segments of the laboratory community are available in the Creatinine Standardization Recommendations section of the website. Also available is a protocol for calibrating creatinine measurements using whole blood devices. The National Institute for Standards and Technology (NIST) released a standard reference material (SRM 967 Creatinine in Frozen Human Serum) for use in establishing calibrations for routine creatinine measurement procedures. SRM 967 was validated to be commutable with native serum samples for many routine creatinine procedures and is useful to establish or verify traceability to an IDMS reference measurement procedure. Establishing calibrations for serum creatinine methods using SRM 967 not only provides a mechanism for ensuring more accurate measurement of serum creatinine, but also enables more accurate estimates of GFR. For clinical laboratories interested in independently checking the calibration supplied by their creatinine reagent suppliers/manufacturers, periodic measurement of NIST SRM 967 should be considered for inclusion in the lab''''s internal quality assurance program. To learn more about SRM 967, including how to purchase it, visit the NIST website, https://www-s.nist.gov/srmors/quickSearch.cfm

Proper citation: Creatinine Standardization Program (RRID:SCR_006441) Copy   

•   Source: SciCrunch Registry

http://omim.org

Online catalog of human genes and genetic disorders, for clinical features, phenotypes and genes. Collection of human genes and genetic phenotypes, focusing on relationship between phenotype and genotype. Referenced overviews in OMIM contain information on all known mendelian disorders and variety of related genes. It is updated daily, and entries contain copious links to other genetics resources.

Proper citation: OMIM (RRID:SCR_006437) Copy   

•   Source: SciCrunch Registry

http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/

Consortium that puts sequences into a chromosome context and provides the best possible reference assembly for human, mouse, and zebrafish via FTP. Tools to facilitate the curation of genome assemblies based on the sequence overlaps of long, high quality sequences.

Proper citation: Genome Reference Consortium (RRID:SCR_006553) Copy   

•   Source: SciCrunch Registry